Latest Breaking News On - Keck school of medicine los angeles - Page 1 : comparemela.com

OCUGEN ANNOUNCES POSITIVE CLINICAL STUDY UPDATE FROM THE PHASE 1/2 TRIAL OF OCU400, A MODIFIER GENE THERAPY PRODUCT CANDIDATE, FOR THE TREATMENT OF RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS

MALVERN - Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study.

Ocugen (OCGN) Reports Positive Clinical Study Update from the Phase 1/2 Trial of OCU400

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity .

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier ...

FavorablesafetyandtolerabilityprofileofOCU400investigationaldrugproductin RP and LCA subjects to dateClinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance